ViiV/Janssen’s two-drug HIV regimen filed in US, EU
ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU.
Read More
Tag: NRTI
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
